Apotex Reports Second-Quarter Results, Raises Fiscal 2027 Guidance

Apotex Health Corp. reported its financial results for the second quarter of fiscal 2027, highlighting strong performance. Alongside the quarterly results, the company announced an upward revision to its guidance for the full fiscal year 2027. As Canada's largest pharmaceutical company, Apotex continues to manage a broad portfolio of generic, biosimilar, and branded medicines.

The announcement reflects the company's current operational momentum and updated expectations for the remainder of the fiscal year.